Quantification of Frataxin-M Protein, a Blood Biomarker of the Rare Disease Friedreich’s Ataxia

Importance of the Topic

Friedreich’s ataxia (FRDA) is the most common hereditary ataxia in the US, leading to progressive neurological decline and life-threatening cardiomyopathy. Accurate measurement of mitochondrial mature frataxin (frataxin-M) in blood cells offers a valuable biomarker for disease severity and potential therapeutic monitoring. Developing a robust, high-throughput quantification method is vital to support large cohort studies and accelerate clinical research.

Objectives and Study Overview

This study compares two mass spectrometry–based workflows for frataxin-M quantification in whole blood: a standard-flow HPLC coupled with an Agilent 6495 triple quadrupole LC/TQ system in multiple reaction monitoring (MRM) mode versus a trap-and-elute nanoflow LC system coupled with high-resolution orbitrap MS in parallel reaction monitoring (PRM) mode. The goal was to evaluate sensitivity, precision, run time, and throughput for clinical-grade biomarker analysis.

Applied Methodology

Whole blood samples from healthy controls and FRDA subjects were lysed, spiked with stable isotope-labeled frataxin-M, and subjected to immunoprecipitation (IP) using anti-frataxin monoclonal antibody cross-linked to protein G magnetic beads. Captured proteins were digested with Asp-N protease, and target peptides were analyzed by LC/MS. Quantification relied on peptide peak area ratios of light and heavy frataxin-M internal standards.

Instrumentation

• Agilent 6495 triple quadrupole LC/TQ system with Agilent 1290 Infinity II UHPLC
• Standard-flow UHPLC-MRM/MS method (0.4 mL/min, 11-minute cycle)
• Nanoflow trap-and-elute LC system with high-resolution orbitrap MS (400 nL/min, 105-minute cycle)

Key Results and Discussion

The standard-flow UHPLC-MRM/MS workflow achieved superior limits of detection (0.08–0.09 ng) and quantification (0.23–0.25 ng) compared to the nanoflow PRM method (LOD 0.17–0.45 ng; LOQ 0.54–1.44 ng). Both methods showed excellent linearity (R2>0.99 for MRM; R2>0.96 for PRM), but the 6495 LC/TQ system delivered five-fold faster peptide separation (4 vs 38 minutes) and reduced total run time for a 40-sample batch from 8 days to less than one day. Frataxin-M levels in FRDA patients (0.3–3.8 ng/mL) inversely correlated with GAA repeat length (R2=0.85), consistent with disease severity.

Benefits and Practical Applications

• High throughput: Enables completion of 40 samples in under 24 hours, facilitating large cohort studies.
• Robust performance: Standard-flow LC/TQ tolerates routine use with minimal maintenance compared to nanoflow systems.
• Clinical relevance: Accurate frataxin-M measurement supports disease monitoring, genotype–phenotype correlations, and therapeutic evaluation.

Future Trends and Opportunities

Integration of standard-flow MRM workflows into clinical laboratories can accelerate biomarker validation and remote patient monitoring. Further automation of IP and digestion steps promises fully streamlined sample-to-data pipelines. Emerging high-throughput MS platforms and multiplexed assays may expand the panel of mitochondrial biomarkers for comprehensive disease profiling.

Conclusion

The Agilent 6495 LC/TQ platform paired with standard-flow UHPLC in MRM mode outperforms a nanoflow PRM strategy for frataxin-M quantification in whole blood by offering superior sensitivity, precision, and dramatically reduced run times. This approach is well suited for high-throughput clinical research and biomarker studies in Friedreich’s ataxia.

References

1. Evans-Galea MV et al. Hum Gene Ther. 2014;25(8):684–93.
2. Pousset F et al. JAMA Neurol. 2015;72(11):1334–41.
3. Lynch DR et al. Ann Clin Transl Neurol. 2019;6(1):15–26.
4. Santos R et al. Antioxid Redox Signal. 2010;13(5):651–90.
5. Gellera C et al. Neurogenetics. 2007;8(4):289–99.
6. Rotig A et al. Nat Genet. 1997;17(2):215–7.
7. Delatycki MB, Bidichandani SI. Neurobiol Dis. 2019;132:104606.
8. Doni D et al. FASEB J. 2021;35(3):e21362.
9. Monfort B et al. Front Neurosci. 2022;16:838335.
10. Sacca F et al. PLoS One. 2011;6(3):e17627.
11. Guo L et al. Anal Chem. 2018;90(3):2216–23.
12. Rodden LN et al. Sci Rep. 2022;12(1):5031.
13. Wang Q et al. Front Neurosci. 2022;16:874768.
14. Blair IA et al. Future Sci OA. 2019;5(6):FSO398.
15. Guo L et al. Sci Rep. 2018;8(1):17043.